A method for standardized postapproval adverse drug reaction (ADR) reporting has been developed and implemented by seven multinational pharmaceutical manufacturers and six regulatory authorities. This is based on a set of uniform definitions, procedures, and a single reporting form, and has been demonstrated to be useful and effective. When regulators and manufacturers develop requirements and systems for ADR reporting they should consider adapting this Council for International Organizations of Medical Science (CIOMS) approach.
Get full access to this article
View all access options for this article.
References
1.
The Council for International Organizations of Medical Sciences. CIOMS Report 1987. Geneva: WHO.
2.
The Council for International Organization of Medical Sciences. CIOMS Report 1989. Publication pending.
3.
FaichGA. Adverse drug reaction monitoring. N Engl J Med.1986;314(24):1589–1592.
4.
FaichGALawsonDHTilsonHHWalkerA. Clinical trials are not enough: Drug development and pharmacoepidemiology. J Clin Res Drug Devel.1987;1(1):75–78.
5.
NichollsJT. The practolol syndrome — a retrospective analysis postmarketing surveillance of adverse reactions to new medicines. Medico-Pharmaceutical Forum.1978; 7.
6.
Anon.Benoxaprofen. Br Med J.1982;285: 459–460.
7.
Anon.CSM update: Withdrawal of nomifensine. Br Med J.1986;293–41.
8.
United Kingdom Medicine Act. Information Letter 41. 1984.
9.
Application for FDA approval to market a new drug or an antibiotic drug.Postmarketing reporting of adverse drug experiences. Fed Reg.1985;50: 7500–7401.
10.
Section 29 of the German Drug Law No. 208, An announcement on notification of side effects. November 5, 1987 (English translation by B. Sickmueller). Bestimnugen zor Anzerge von Welsenvikungen. Pharm Ind.1988;50(5):532–543.
